Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 585 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... September 18, 2019 Today is Giving Tuesday December 1, 2020 Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... April 22, 2021 Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... March 1, 2021 Load more HOT NEWS Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... ¿El azúcar provoca cáncer? Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in... Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from...
